The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease
- Laboratory of Neuromodulation and Behavior, Department of Neurosciences, Medical University of South Carolina, Charleston, SC, USA
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% of the population over age 60. In those patients cognitive dysfunction is a persistent issue that impairs quality of life and productivity. Neuropathological studies demonstrate significant damage in brain regions outside the nigral dopamine (DA) system, including early degeneration of locus coeruleus norepinephrine (LC-NE) neurons, yet discussion of PD and treatment focus has remained dopaminergic-based. Motor symptoms benefit from DA replacement for many years, but other symptoms including several cognitive deficits continue unabated. Recent interest in non-DA substrates of PD highlights early involvement of LC-NE neurons and provides evidence for a prodromal phase, with cognitive disturbance, even in sporadic PD. We outline insights from basic research in LC-NE function to clinical and pathological evidence highlighting a role for NE in PD cognitive dysfunction. We propose that loss of LC-NE regulation, particularly in higher cortical regions, critically underlies certain cognitive dysfunctions in early PD. As a major unmet need for patients, research and use of NE drugs in PD may provide significant benefits for cognitive processing.
Keywords: Parkinson's disease, norepinephrine, locus coeruleus, executive dysfunction
Citation: Vazey EM and Aston-Jones G (2012) The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front. Behav. Neurosci. 6:48. doi: 10.3389/fnbeh.2012.00048
Received: 09 April 2012; Accepted: 09 July 2012;
Published online: 25 July 2012.
Edited by:Angela J. Yu, University of California, San Diego, USA
Reviewed by:Charles W. Wilkinson, University of Washington, USA
Sebastien Bouret, Institut du Cerveau et de la Moelle epiniere, France
Copyright © 2012 Vazey and Aston-Jones. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Elena M. Vazey and Gary Aston-Jones, Laboratory of Neuromodulation and Behavior, Department of Neurosciences, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA. e-mail: firstname.lastname@example.org; email@example.com